| Morphic Ethical Equities Fund Limited (MEC) ORDINARY FULLY PAID |
Financials |
$41 |
MEC Monthly Performance Report March 2026
|
20 Apr 2026 10:16AM |
$1.210 |
$1.355 |
risen by
11.98%
|
|
| AnteoTech Limited (ADO) ORDINARY FULLY PAID |
Materials |
$91 |
Quarterly Activities/Appendix 4C Cash Flow Report
|
20 Apr 2026 10:11AM |
$0.011 |
$0.028 |
risen by
154.55%
|
|
ADO - Price-sensitive ASX Announcement
Full Release
Key Points
- AnteoTech's focus on commercial execution in ABT and LS divisions.
- Validation of Ultranode™ 70 and 95 by international partners.
- Ongoing Joint Development Agreement negotiations for Ultranode™ 95.
- Market expansion through new partnerships and international industry events.
- Cash balance of A$3.291 million with no debt as of March 31, 2026.
- Successful capital raise to support sales and marketing initiatives.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Tartana Minerals Limited (TAT) ORDINARY FULLY PAID |
Materials |
$8 |
Heap Restack Complete and Plant Upgrade Advances
|
20 Apr 2026 10:09AM |
$0.021 |
$0.020 |
fallen by
4.76%
|
|
TAT - Price-sensitive ASX Announcement
Full Release
Key Points
- Completion of heap restack program with 50,000 tonnes stacked
- Focus on higher-grade copper zones for extraction
- Preliminary copper grades consistent with 0.22% Cu
- Advanced fabrication of new chiller circuit for plant upgrade
- Plant upgrade to improve reliability and throughput
- Copper sulphate production restart expected within three weeks
- First shipment to offtaker targeted for mid-May 2026
- Copper sulphate pricing based on LME copper prices
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Orpheus Uranium Limited (ORP) ORDINARY FULLY PAID |
Materials |
$29 |
Quarterly Cashflow Report - March 2026 - Amended
|
20 Apr 2026 10:07AM |
$0.059 |
$0.083 |
risen by
40.68%
|
|
| Atomic Eagle Ltd (AEU) ORDINARY FULLY PAID |
Materials |
$164 |
Board Changes
|
20 Apr 2026 10:02AM |
$0.465 |
$0.430 |
fallen by
7.53%
|
|
| Arovella Therapeutics Limited (ALA) ORDINARY FULLY PAID |
Health Care |
$82 |
Arovella Presents Poster at AACR Annual Meeting
|
20 Apr 2026 10:01AM |
$0.081 |
$0.068 |
fallen by
16.05%
|
|
| Peoplein Limited (PPE) ORDINARY FULLY PAID |
Industrials |
$74 |
Final Director's Interest Notice - Ross Thompson
|
20 Apr 2026 10:01AM |
$0.620 |
$0.680 |
risen by
9.68%
|
|
| Sunshine Metals Limited (SHN) ORDINARY FULLY PAID |
Materials |
$98 |
Further Shallow High-Grade Results incld. 14m @ 12.38g/t Au
|
20 Apr 2026 10:00AM |
$0.030 |
$0.028 |
fallen by
6.67%
|
|
SHN - Price-sensitive ASX Announcement
Full Release
Key Points
- Sunshine Metals Limited completed a grade control drill program at Liontown.
- The program aimed to support mine planning and improve resource confidence.
- A significant result was 14m at 12.38g/t Au from 79m.
- The drilling expanded from 84 to 121 holes due to early high-grade results.
- Further resource drilling at Liontown Au Panel aims for underground mining development.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| ikeGPS Group Limited (IKE) ORDINARY FULLY PAID FOREIGN EXEMPT NZX |
Information Technology |
$202 |
Date for release of IKEs quarterly performance update
|
20 Apr 2026 10:00AM |
$0.900 |
$1.040 |
risen by
15.56%
|
|
| Nexalis Therapeutics Ltd (NX1) ORDINARY FULLY PAID |
Health Care |
$3 |
Significant Milestone - First Patient Screened IRX-211 Ph2
|
20 Apr 2026 9:59AM |
$0.023 |
$0.013 |
fallen by
43.48%
|
|
NX1 - Price-sensitive ASX Announcement
Full Release
Key Points
- First patient screened for Phase 2 trial of IRX-211 for Breakthrough Cancer Pain.
- IRX-211 designed as inhaled therapy for rapid, predictable relief.
- Phase 2 trial is multicentre, randomised, double-blind, placebo-controlled.
- Trial involves dose titration and cross-over study design.
- Approximately 156 patients targeted for enrolment.
- Significant milestone marking transition to controlled clinical evaluation.
- BTcP is inadequately served by current therapies, rapid onset requires new solutions.
- IRX-211 positions for future development and partnering opportunities.
- Nexalis Therapeutics aims for U.S. FDA approval through 505(b)(2) pathways.
- Funding partnership facilitates development of BTcP, Panic Disorder, and Treatment-Resistant Depression treatments.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| RPM Automotive Group Limited (RPM) ORDINARY FULLY PAID |
Consumer Discretionary |
$4 |
RPM Announces Leadership Transition
|
20 Apr 2026 9:57AM |
$0.026 |
$0.015 |
fallen by
42.31%
|
|
RPM - Price-sensitive ASX Announcement
Full Release
Key Points
- Clive Finkelstein steps down as CEO of RPM Automotive Group.
- Roy Norris appointed as new CEO, effective immediately.
- Roy Norris has extensive experience in automotive and industrial sectors.
- RPM Board confident in Norris's capability to drive strategic growth.
- RPM Automotive is expanding its footprint in the Australian automotive aftermarket sector.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Peel Mining Limited (PEX) ORDINARY FULLY PAID |
Materials |
$143 |
Quarterly Activities/Appendix 5B Cash Flow Report
|
20 Apr 2026 9:56AM |
$0.155 |
$0.160 |
risen by
3.23%
|
|
PEX - Price-sensitive ASX Announcement
Full Release
Key Points
- Peel Mining Limited's South Cobar Copper Project will be acquired by Aeris Resources through a Scheme of Arrangement.
- Peel Mining is demerging its remaining assets into a new company, Spectre Metals.
- Peel Mining completed an initial drilling program confirming the continuity of mineralisation in the Southern Nights Complex.
- The company held $14.9 million in cash and cash equivalents at the end of the March 2026 quarter.
- Net operating cash outflows were $1.58 million, and net investing cash flows were $1.32 million.
- Payments to the Directors totaled $155,000 during the quarter.
- The report includes Appendix 5B, detailing cash flows and financial activities.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| ioneer Ltd (INR) ORDINARY FULLY PAID |
Materials |
$477 |
Notice of Annual General Meeting/Proxy Form
|
20 Apr 2026 9:55AM |
$0.135 |
$0.155 |
risen by
14.81%
|
|
| Australian Foundation Investment Company Limited (AFI) ORDINARY FULLY PAID |
Financials |
$8,316 |
Weekly Estimated NTA as at 17 April 2026
|
20 Apr 2026 9:55AM |
$6.640 |
$6.730 |
risen by
1.36%
|
|
| WAM Active Limited (WAA) ORDINARY FULLY PAID |
Financials |
$150 |
Kate Thorley Appendix 3Y
|
20 Apr 2026 9:53AM |
$0.995 |
$1.010 |
risen by
1.51%
|
|
| Haranga Resources Limited (HAR) ORDINARY FULLY PAID |
Materials |
$45 |
Proposed change of Company Name
|
20 Apr 2026 9:52AM |
$0.145 |
$0.100 |
fallen by
31.03%
|
|
| AMCIL Limited (AMH) ORDINARY FULLY PAID |
Financials |
$277 |
Weekly Estimated NTA as at 17 April 2026
|
20 Apr 2026 9:52AM |
$0.925 |
$0.880 |
fallen by
4.86%
|
|
| Botanix Pharmaceuticals Ltd (BOT) ORDINARY FULLY PAID |
Health Care |
$52 |
Notification regarding unquoted securities - BOT
|
20 Apr 2026 9:49AM |
$0.037 |
$0.019 |
fallen by
48.65%
|
|
| Lumos Diagnostics Holdings Limited (LDX) ORDINARY FULLY PAID |
Health Care |
$99 |
Quarterly Activities/Appendix 4C Cash Flow Report
|
20 Apr 2026 9:49AM |
$0.195 |
$0.105 |
fallen by
46.15%
|
|
LDX - Price-sensitive ASX Announcement
Full Release
Key Points
- FebriDx® received US FDA 510(k) clearance with a CLIA waiver, expanding its market reach significantly.
- Milestone payments were triggered by the successful 510(k) application, totaling US$5.72 million.
- Revenue for Q3 FY26 was US$4.8 million, a 37% increase compared to the previous corresponding period.
- Operating cash outflow for the quarter was US$2.8 million, with investments in inventory production.
- Lumos completed a A$20 million placement to strengthen its financial position.
- Cash balance at the end of Q3 FY26 was US$1.1 million, with additional funding expected from milestone payments.
- The Share Purchase Plan (SPP) offered additional shares to eligible shareholders with benefits attached.
- Continued focus on increasing FebriDx® sales in the US, progressing the BARDA paediatric study, and Hologic fFN project.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Pure One Corporation Limited (P1E) ORDINARY FULLY PAID |
Energy |
$18 |
Update on proposed sale of 40% of Turquoise Group for $5M
|
20 Apr 2026 9:49AM |
$0.066 |
$0.044 |
fallen by
33.33%
|
|
| EBR Systems Inc (EBR) CDI 10:1 US PERSON PROHIBITED EXCLUDING QIB |
Health Care |
$246 |
EBR Systems to Participate at Heart Rhythm 2026
|
20 Apr 2026 9:48AM |
$0.650 |
$0.385 |
fallen by
40.77%
|
|
| Omnia Metals Group Limited (OM1) ORDINARY FULLY PAID |
Materials |
$7 |
USA Critical Minerals Portfolio Presentation
|
20 Apr 2026 9:47AM |
$0.021 |
$0.019 |
fallen by
9.52%
|
|
| WAM Income Maximiser Limited (WMX) ORDINARY FULLY PAID |
Financials |
$329 |
Kate Thorley Appendix 3Y
|
20 Apr 2026 9:47AM |
$1.615 |
$1.700 |
risen by
5.26%
|
|
| Diablo Resources Limited (DBO) ORDINARY FULLY PAID |
Materials |
$4 |
Silver - Antimony Mineralisation Confirmed at Star Range
|
20 Apr 2026 9:47AM |
$0.018 |
$0.014 |
fallen by
22.22%
|
|
DBO - Price-sensitive ASX Announcement
Full Release
Key Points
- Diablo Resources Limited reports on the confirmation of silver-antimony mineralisation at the Star Range project.
- The project is located within the Star Range in southwestern Utah, known for historical mining activity.
- Mineralisation occurs as structurally controlled manto-replacement style and breccia vein systems.
- The project's geological structure includes block-faulted sediments intruded by granitic compositions.
- Numerous old workings were exploited in the late 1800s for base and precious metals.
- The announcement includes detailed location and results of soil and rock sampling studies.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| 4DMedical Limited (4DX) ORDINARY FULLY PAID |
Health Care |
$2,846 |
GSK contract, UK clearance for CTVQ, and ASX 200 inclusion
|
20 Apr 2026 9:46AM |
$5.840 |
$4.780 |
fallen by
18.15%
|
|
4DX - Price-sensitive ASX Announcement
Full Release
Key Points
- Contract with GlaxoSmithKline for lung imaging analytics.
- UKCA certification for CT:VQ™ in the UK.
- Inclusion in the S&P/ASX 200 Index.
- 4DMedical is a leader in respiratory imaging technology.
- CT:VQ™ has FDA clearance and a growing presence in US medical centers.
- Milestones reinforce 4DMedical's position as a global platform company.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
Call 1300 880 160
Start a chat
Schedule a call
